Anti-melanoma antibody MG-21 for diagnosis and therapy of human tumors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 8, 1991
Grant Date -
N/A
app pub date -
Feb 20, 1986
filing date -
Feb 20, 1986
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
An antibody MG-21 which is directed against a tumor-associated glycolipid antigen and which is capable of activating serum complement or antibody dependent cellular cytoxicity is described. This antibody finds use in the therapy of cancers particularly melanoma and glioma. Proper administration of the antibody results in lysis of the tumor cells in vivo.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully